Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 28953921 | HLA-CLASS I (HLA CLASS II) | viremia | NA | NA | NA | lack_of_evidence | |
| reduced peak viremia was also positively correlated with a decreased number of hla class i allele associated polymorphisms in gag sequences in the rebounding virus population (p = 0.012). | |||||||
| 29333522 | HLA-CLASS I (HLA CLASS II) | viremia | NA | NA | NA | unclassified | |
| we performed a pooled analysis of 103 participants from 4 aids clinical trials group ati studies to identify the association between hla class i alleles with hiv reservoir size and viral rebound timing.methodstotal hiv dna and cell-associated hiv rna (ca-rna) were quantified in pre-ati peripheral blood mononuclear cell samples, and residual plasma viremia was measured using the single-copy assay. | |||||||
| 29333522 | HLA-B (HLA-B) | viremia | NA | NA | NA | positive+negation | |
| hla class i typing was performed, and we generated an odds ratio (or) of predicted hla effect on hiv viremia control for each individual and compared this with time to viral rebound, and levels of hiv dna and ca-rna.resultsthere was no significant association between the hla ors and levels of hiv dna or ca-rna, but carriage of protective hla-b alleles (lower or scores) was associated with delayed viral rebound (p = 0.02). | |||||||
| 29445759 | HLA-C (HLA-C) | viremia | NA | NA | rs9264942 | unclassified | |
| several genome-wide association studies have identified a polymorphism located 35 kb upstream of the coding region of hla-c gene (rs9264942 | |||||||
| 30028417 | HLA-DR (HLA-DR) | viremia | NA | NA | NA | unclassified | |
| in general, cd8 t-cell clusters associated with poorly controlled hcmv viremia lacked markers of activation or terminal differentiation including cd38, cd69, cd25, cd57, and hla-dr. we also measured the production of 8 hcmv-specific effector molecules (tnfa, ifng, interleukin 2, granzyme b, perforin, macrophage inflammatory protein 1b, interleukin 10, and cd107a) in cd8 t cells. | |||||||
| 30463516 | HLA (HLA) | viremia | NA | NA | NA | unclassified | |
| affected recipients were older, had more hla mismatches, and were more likely to have had bk viremia, cmv viremia and invasive fungal infections than matched controls. | |||||||
| 30463516 | HLA (HLA) | invasive fungal infections | NA | NA | NA | unclassified | |
| affected recipients were older, had more hla mismatches, and were more likely to have had bk viremia, cmv viremia and invasive fungal infections than matched controls. | |||||||
| 30746369 | HLA (HLA) | viremia | NA | NA | NA | unclassified | |
| our multivariable model demonstrated that afro-caribbean ethnicity, panel-reactive antibody > 50%, hla mismatching > 4, and rejection were independent risk factors for bk-virus viremia whereas cytomegalovirus prophylaxis was protective. | |||||||
| 30798036 | HLA-CLASS I (HLA-I) | viremia | NA | NA | NA | positive | |
| the potential association between prolonged viremia and higher ability for immune evasion in denv-2 patients was further corroborated with the observation of poorer hla-i binding affinity in ctl epitopes observed in ns2a sequences retrieved from patients with >5 days of illness, compared to those with <=5 days. | |||||||
| 30859662 | HLA (HLA) | voriconazole | NA | amphotericin | NA | positive | |
| NA | |||||||
Copyright 2024